Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Kolberg on Cost-Effectiveness of Pertuzumab in HER2-Positive Breast Cancer

Hans-Christian Kolberg, MD
Published: Thursday, Dec 10, 2015



Hans-Christian Kolberg, MD, doctor of Medicine, Marien Hospital Bottrop in Bottrop, Germany, discusses the cost-effectiveness of pertuzumab as a treatment for patients with HER2-positive breast cancer, based off of findings from a study published in the Journal of Clinical Oncology.

In the study, the authors suggest that pertuzumab is not a cost-effective therapy for patients. However, Kolberg explains, the agent does demonstrate improved survival by 1.8 years, which the authors equated to totalling $100,000.

Kolberg says that targeted therapies, especially anti-angiogenic agents, are becoming more expensive. The question of how much money society is willing to spend on medication for longer survival and improved quality of life, however, should be a societal, ethical question—not a medical question. 


Hans-Christian Kolberg, MD, doctor of Medicine, Marien Hospital Bottrop in Bottrop, Germany, discusses the cost-effectiveness of pertuzumab as a treatment for patients with HER2-positive breast cancer, based off of findings from a study published in the Journal of Clinical Oncology.

In the study, the authors suggest that pertuzumab is not a cost-effective therapy for patients. However, Kolberg explains, the agent does demonstrate improved survival by 1.8 years, which the authors equated to totalling $100,000.

Kolberg says that targeted therapies, especially anti-angiogenic agents, are becoming more expensive. The question of how much money society is willing to spend on medication for longer survival and improved quality of life, however, should be a societal, ethical question—not a medical question. 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x